Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 5.69
AMEX:BTX's Cash-to-Debt is ranked lower than
61% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. AMEX:BTX: 5.69 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:BTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 5.69
Equity-to-Asset 0.91
AMEX:BTX's Equity-to-Asset is ranked higher than
89% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMEX:BTX: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:BTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -45.87  Med: 0.52 Max: 0.99
Current: 0.91
-45.87
0.99
Debt-to-Equity 0.02
AMEX:BTX's Debt-to-Equity is ranked higher than
93% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMEX:BTX: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
AMEX:BTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.49  Med: -0.18 Max: 0.07
Current: 0.02
-17.49
0.07
Debt-to-EBITDA -0.07
AMEX:BTX's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. AMEX:BTX: -0.07 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMEX:BTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69  Med: -0.03 Max: 0
Current: -0.07
-0.69
0
Piotroski F-Score: 4
Altman Z-Score: 11.59
Beneish M-Score: 2.60
WACC vs ROIC
13.40%
-31.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1264.18
AMEX:BTX's Operating Margin % is ranked lower than
79% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. AMEX:BTX: -1264.18 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:BTX' s Operating Margin % Range Over the Past 10 Years
Min: -1262.65  Med: -530.02 Max: -116.83
Current: -1264.18
-1262.65
-116.83
Net Margin % 1901.61
AMEX:BTX's Net Margin % is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. AMEX:BTX: 1901.61 )
Ranked among companies with meaningful Net Margin % only.
AMEX:BTX' s Net Margin % Range Over the Past 10 Years
Min: -989.69  Med: -337.07 Max: 566.81
Current: 1901.61
-989.69
566.81
ROE % 46.44
AMEX:BTX's ROE % is ranked higher than
97% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. AMEX:BTX: 46.44 )
Ranked among companies with meaningful ROE % only.
AMEX:BTX' s ROE % Range Over the Past 10 Years
Min: -381.18  Med: -127.26 Max: 46.71
Current: 46.44
-381.18
46.71
ROA % 40.20
AMEX:BTX's ROA % is ranked higher than
98% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AMEX:BTX: 40.20 )
Ranked among companies with meaningful ROA % only.
AMEX:BTX' s ROA % Range Over the Past 10 Years
Min: -624.96  Med: -56.07 Max: 28.3
Current: 40.2
-624.96
28.3
ROC (Joel Greenblatt) % -863.33
AMEX:BTX's ROC (Joel Greenblatt) % is ranked lower than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. AMEX:BTX: -863.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:BTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10626.09  Med: -2097.07 Max: -902.46
Current: -863.33
-10626.09
-902.46
3-Year Revenue Growth Rate -10.40
AMEX:BTX's 3-Year Revenue Growth Rate is ranked lower than
65% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMEX:BTX: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:BTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -51.6  Med: 6.15 Max: 106.8
Current: -10.4
-51.6
106.8
3-Year EBITDA Growth Rate -17.20
AMEX:BTX's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. AMEX:BTX: -17.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:BTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.5  Med: 7.75 Max: 70.2
Current: -17.2
-48.5
70.2
GuruFocus has detected 6 Warning Signs with BioTime Inc AMEX:BTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:BTX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BTX Guru Trades in Q2 2015

Jim Simons 165,000 sh (New)
» More
Q3 2015

BTX Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q1 2017

BTX Guru Trades in Q1 2017

Jim Simons 105,822 sh (New)
» More
Q2 2017

BTX Guru Trades in Q2 2017

Jim Simons 125,607 sh (+18.70%)
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:SYBX, LSE:DDDD, TSE:4564, XPAR:COX, NAS:BSTC, XKRX:182400, NAS:IDRA, OTCPK:AXIM, XPAR:ERYP, NAS:NVAX, XTER:MDG1, XSWX:SKIN, NAS:CNCE, WAR:MAB, NAS:EDGE, NAS:CRVS, NAS:RARX, XKRX:083790, NAS:CDXS, NAS:SYRS » details
Traded in other countries:BT3.Germany, BTX.Israel,
Headquarter Location:USA
BioTime Inc focuses regenerative medicine technologies in ophthalmology, soft tissue reconstruction, and the local delivery of cells and therapeutics.

BioTime Inc is a clinical-stage biotechnology company. Its objective is the development and commercialization of novel therapies developed with the help of the company's core technology platforms. The core therapeutic technologies are based on pluripotent stem cells that can become any of the cell types in the human body. Pluripotent stem cells have potential applications in many areas of medicine, including several age-related degenerative diseases and conditions for which there presently are no cures. The product portfolio includes Renevia, a potential treatment for HIV-related facial lipoatrophy; AST-VAC1, a cancer immunotherapy; and OpRegen, a potential therapy derived from pluripotent stem cells to treat the dry form of age-related macular degeneration.

Ratios

vs
industry
vs
history
PE Ratio 4.40
BTX's PE Ratio is ranked higher than
94% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. BTX: 4.40 )
Ranked among companies with meaningful PE Ratio only.
BTX' s PE Ratio Range Over the Past 10 Years
Min: 3.18  Med: 5.24 Max: 18.57
Current: 4.4
3.18
18.57
PE Ratio without NRI 4.40
BTX's PE Ratio without NRI is ranked higher than
95% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. BTX: 4.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
BTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.18  Med: 5.24 Max: 18.57
Current: 4.4
3.18
18.57
Price-to-Owner-Earnings 4.15
BTX's Price-to-Owner-Earnings is ranked higher than
92% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. BTX: 4.15 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.14  Med: 4.94 Max: 13.59
Current: 4.15
3.14
13.59
PB Ratio 1.66
BTX's PB Ratio is ranked higher than
81% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BTX: 1.66 )
Ranked among companies with meaningful PB Ratio only.
BTX' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 9.54 Max: 45.12
Current: 1.66
1.6
45.12
PS Ratio 82.50
BTX's PS Ratio is ranked lower than
83% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. BTX: 82.50 )
Ranked among companies with meaningful PS Ratio only.
BTX' s PS Ratio Range Over the Past 10 Years
Min: 4.71  Med: 42.58 Max: 106.11
Current: 82.5
4.71
106.11
EV-to-EBIT -7.64
BTX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. BTX: -7.64 )
Ranked among companies with meaningful EV-to-EBIT only.
BTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -65.8  Med: -7.4 Max: -2.5
Current: -7.64
-65.8
-2.5
EV-to-EBITDA -8.29
BTX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. BTX: -8.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
BTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.3  Med: -8.2 Max: -2.7
Current: -8.29
-72.3
-2.7
EV-to-Revenue 96.62
BTX's EV-to-Revenue is ranked lower than
80% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. BTX: 96.62 )
Ranked among companies with meaningful EV-to-Revenue only.
BTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 45.8 Max: 117.3
Current: 96.62
4.2
117.3
PEG Ratio 0.44
BTX's PEG Ratio is ranked higher than
93% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. BTX: 0.44 )
Ranked among companies with meaningful PEG Ratio only.
BTX' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: 0.44
Current Ratio 1.89
BTX's Current Ratio is ranked lower than
75% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BTX: 1.89 )
Ranked among companies with meaningful Current Ratio only.
BTX' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.76 Max: 76
Current: 1.89
0.02
76
Quick Ratio 1.89
BTX's Quick Ratio is ranked lower than
72% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. BTX: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
BTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.73 Max: 74
Current: 1.89
0.02
74
Days Sales Outstanding 333.76
BTX's Days Sales Outstanding is ranked lower than
96% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. BTX: 333.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
BTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.3  Med: 88.57 Max: 333.76
Current: 333.76
71.3
333.76
Days Payable 2.00
BTX's Days Payable is ranked lower than
92% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. BTX: 2.00 )
Ranked among companies with meaningful Days Payable only.
BTX' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 1291.37 Max: 5165.44
Current: 2
2
5165.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.90
BTX's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BTX: -21.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.3  Med: -13.95 Max: -2.1
Current: -21.9
-27.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 37.71
BTX's Price-to-Net-Current-Asset-Value is ranked lower than
90% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. BTX: 37.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 18.96 Max: 361
Current: 37.71
1.05
361
Price-to-Tangible-Book 1.74
BTX's Price-to-Tangible-Book is ranked higher than
84% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. BTX: 1.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.03  Med: 15.13 Max: 137.1
Current: 1.74
1.03
137.1
Price-to-Median-PS-Value 1.94
BTX's Price-to-Median-PS-Value is ranked lower than
84% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BTX: 1.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.08 Max: 31.05
Current: 1.94
0.11
31.05
Price-to-Graham-Number 0.59
BTX's Price-to-Graham-Number is ranked higher than
95% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. BTX: 0.59 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.58  Med: 1.01 Max: 1.75
Current: 0.59
0.58
1.75
Earnings Yield (Greenblatt) % -13.09
BTX's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. BTX: -13.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -39.8  Med: -13.6 Max: -1.5
Current: -13.09
-39.8
-1.5

More Statistics

Revenue (TTM) (Mil) $3.35
EPS (TTM) $ 0.60
Beta1.82
Short Percentage of Float9.26%
52-Week Range $2.47 - 3.97
Shares Outstanding (Mil)126.86

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.46
EPS without NRI ($) -0.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}